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Abstract
 
Major histocompatibility complex (MHC) class I ligands are mainly produced by the protea-
some. Herein, we show that the processing of antigens is regulated by two distinct pathways,
one requiring PA28 and the other hsp90. Both hsp90 and PA28 enhanced the antigen process-
ing of ovalbumin (OVA). Geldanamycin, an inhibitor of hsp90, almost completely suppressed
OVA antigen presentation in PA28
 
 
 
 
 
/
 
 
 
/
 
 
 
 
 
/
 
 
 
 lipopolysaccharide blasts, but not in wild-type
cells, indicating that hsp90 compensates for the loss of PA28 and is essential in the PA28-inde-
pendent pathway. In contrast, treatment of cells with interferon (IFN)-
 
 
 
, which induces PA28
expression, abrogated the requirement of hsp90, suggesting that IFN-
 
 
 
 enhances the PA28-
dependent pathway, whereas it diminishes hsp90-dependent pathway. Importantly, IFN-
 
 
 
 did
not induce MHC class I expressions in PA28-deficient cells, indicating a prominent role for
PA28 in IFN-
 
 
 
–stimulated peptide supply. Thus, these two pathways operate either redun-
dantly or specifically, depending on antigen species and cell type.
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Introduction
 
Intracellular or endogenous antigens are processed by the
proteasome, generating MHC class I ligands (equivalent
to CTL epitopes) recognized by CD8
 
 
 
T cells (1–3). The
20S proteasome consists of two outer 
 
 
 
-rings and two
 
inner 
 
 
 
-rings, stacked in the order of 
 
    
 
. Both rings
comprise seven 
 
 
 
- or 
 
 
 
-subunits. Substrate proteins are
thought to go through the 
 
 
 
-ring of the proteasome in
order to reach the internal 
 
 
 
-ring cavity where the cata-
lytic sites are located. As the pore of the 
 
 
 
-ring is very
narrow or almost closed, substrate access is usually pre-
vented (4), and thus the 20S proteasome by itself cannot
generate peptides efficiently. To operate active proteoly-
sis, the enzyme needs to associate with regulatory com-
plexes to allow proteins or peptides to access the catalytic
sections.
 To date, two types of regulatory complexes have been
identified in the cell. One is the 19S regulatory complex
(also called PA700), comprising multiple subunits including
six ATPases, which binds to the 20S proteasome to form
the 26S proteasome capable of degrading ubiquitinated
proteins in an ATP-dependent manner (5). The other is
PA28 or the 11S regulator (REG) that greatly stimulates
the peptidase activity of the 20S proteasome but does not
assist the degradation of large proteins, even if they have al-
ready been ubiquitinated (6). PA28 is composed of two
homologous subunits, PA28
 
 
 
 and PA28
 
 
 
.
 These two subunits assemble into a heterohexamer
(
 
 
 
3
 
 
 
3) with alternating 
 
 
 
 and 
 
 
 
 subunits (7), or a hetero-
heptamer (
 
 
 
3
 
 
 
4 or a mixture of 
 
 
 
3
 
 
 
4 and 
 
 
 
4
 
 
 
3) (8) with
a mass of 
 
 
 
200 kD. PA28 is known to be directly associ-
ated with the 20S proteasome, forming the ‘football-shaped
proteasome’ in which PA28 is attached to both ends of the
central 20S proteasome or the ‘hybrid proteasome’ com-
prising the 20S proteasome armed by PA28 on one side
and PA700 on the other (2, 9).
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PA28 and hsp90 in MHC Class I Antigen Processing
 
Evidence indicates that PA28 accelerates the in vitro
processing of MHC class I ligands from their polypeptide
precursors by the 20S proteasome in a coordinated dual-
cleavage manner (10, 11). In vivo analysis has shown also
that overexpression of PA28
 
 
 
 subunit enhances the pro-
cessing of some viral epitopes in cells (12). Moreover, it
was reported that mice deficient in the PA28
 
 
 
 gene have
defective production of CTLs after viral infection, probably
due to impaired assembly of the ‘immunoproteasome’ (13),
a modified version of the 20S proteasome whose three
constitutively expressed 
 
 
 
-type subunits (X/MB1, Y/delta,
and Z) are replaced by IFN-
 
 
 
–inducible subunits (low-
molecular weight polypeptide [LMP]7, LMP2, and multi-
catalytic endopeptidase complex-like [MECL]-1, respec-
tively) (2, 14).
These findings indicate that PA28 plays an important
role in the processing of MHC I class ligands. In contrast,
we recently showed that induction of the immunoprotea-
some by IFN-
 
 
 
 is not impaired in PA28
 
 
 
 
 
/
 
 
 
/
 
 
 
 
 
/
 
 
 
 cells
and that specific CTLs are normally generated against
OVA
 
257–264
 
 epitope, and influenza virus A (PR-8) derived
K
 
b
 
- and D
 
b
 
-restricted NS2 and NP antigen peptides in
these knockout mice, whereas processing of an epitope de-
rived from a tumor antigen of murine B16 melanoma, ty-
rosinase-related protein (TRP2)
 
*
 
181–188
 
 is entirely depen-
dent on PA28 (15). These observations suggest that
PA28
 
  
 
 is not a prerequisite for antigen processing in gen-
eral, but plays an essential role in the processing of certain
antigens. Hence, it is likely that there exists a compensatory
system(s) for PA28 function in the processing of antigens,
but the entity remains unknown so far.
The molecular chaperone hsp90 is one of the most
abundant proteins in eukaryotic cells, comprising 1–2% of
total cellular proteins even in conditions of nonstress.
Hsp90 is an evolutionarily conserved protein and contrib-
utes to a wide variety of fundamentally common and spe-
cies-specific processes in cells (16–18). For example, it is
essential for maintenance of functional integrity of various
fragile proteins, such as steroid hormone receptors and
many of protein kinases (18). 
It is also notable that hsp90 functions as a protein-fold-
ing machinery collaborating with other chaperone mole-
cules, such as Hsp70 and hsp40, and cochaperones con-
taining p23 and Hop (16, 17). Indeed, Hsp90 can bind
nonnative proteins through N- and COOH-terminal do-
mains for refolding (17). In addition, hsp90 appears to be
closely linked to the protein degradation in the cell. In
fact, hsp90 directly associates with the 20S proteasome,
and thus can influence the enzyme activity (19, 20). Re-
cent studies have also shown that hsp90 links misfolded
proteins of aberrant structures to the ubiquitination path-
way for selective elimination (21). It is noteworthy that
the COOH-terminal domain is involved in binding the
antigenic octapeptide of vesicular stomatitis virus G pro-
tein (22). 
Evidence also suggests that hsp90 binds to tumor-associ-
ated MHC class I ligands or their precursors (23). The latter
part of these observations strongly suggests that hsp90
might be involved in MHC class I antigen presentation,
but the molecular basis of such role is still unclear. Using
x-ray crystallographic analysis, Prodromou et al. (24) indi-
cated that hsp90 comprises a deep pocket containing bind-
ing sites for geldanamycin (GA), an anti-cancer agent, as
well as ATP/ADP at the NH
 
2
 
-terminal region. Therefore,
the ATPase and hence chaperone activity of hsp90 is inhib-
ited by ansamycin drugs such as GA or herbimycin A (HA),
indicating that GA and HA could serve as hsp90-specific
inhibitors (25).
Here, we examined the roles of PA28 and hsp90 in the
MHC class I–restricted antigen processing using GA and
HA (inhibitors of hsp90) and cells derived from mice lack-
ing PA28
 
 
 
 and PA28
 
 
 
. We show that both PA28 and
hsp90 accelerate the processing of C- but not NH
 
2
 
-termi-
nal flanking regions of MHC class I ligands. 
Importantly, the results showed that hsp90 is essential for
compensating the loss of PA28 function in LPS blasts of
PA28
 
 
 
 
 
/
 
 
 
/
 
 
 
 
 
/
 
 
 
 mice, resulting in nearly normal antigen
presentation of OVA
 
257–264
 
. In addition, we show that
IFN-
 
 
 
–induced up-regulation of MHC class I is defective
in PA28
 
 
 
 
 
/
 
 
 
/
 
 
 
 
 
/
 
 
 
 macrophages and dendritic cells. Our
data provide novel insights into the roles of PA28 and
hsp90 in MHC class I antigen processing.
 
Materials and Methods
 
Reagents, Proteins, and Peptides.
 
Hsp90, hsc70, and gp96 were
purified from ascitic fluid from mice injected with RL 1 cells as
described previously (23). cDNA of murine PA28
 
 
 
 was amplified
by reverse transcription (RT)-PCR from the mRNA of EL4 cells
and cloned into 5
 
 
 
 BamHI and 3
 
 
 
 KpnI sites of the pQE31 ex-
pression vector (QIAGEN). The protein expression was induced
in 
 
Escherichia coli
 
 strain M15 and purified as described previously
(26). The OVA
 
257–269
 
 (SIINFEKLTEWTS), OVA
 
248–264
 
 (EVS-
GLEQLESIINFEKL), and OVA
 
248–269
 
 (EVSGLEQLESIINFEK-
LTEWTS) peptides were synthesized by standard solid phase
methods using F-mock chemistry in a peptide synthesizer
(AMS422; Applied Biosystems) and purified by reversed-phase
HPLC on a C8 column. TRP2
 
181–193
 
 (VYDFFVWLHYYSV)
was purchased from SAWADY Technology Co. GA was pur-
chased from Sigma-Aldrich. HA was provided by Dr. Y. Uehara,
the National Institute of Infectious Diseases, Tokyo, Japan.
 
Cells and Culture.
 
E.G7 is an OVA cDNA transfected EL4
line (27). OVA
 
257–264
 
 and TRP2
 
181–188
 
 specific CTLs were in-
duced from spleen cells of mice immunized with these peptides
fused to hsc70 as described previously (26) and maintained by
weekly stimulation with E.G7 and B16 melanoma cells, respec-
tively, in the presence of syngeneic feeder cells and IL-2. LPS
blasts and murine embryonic fibroblasts (MEFs) were prepared
from PA28
 
 
 
 
 
/
 
 
 
/
 
 
 
 
 
/
 
 
 
 and PA28
 
 
 
 
 
/
 
 
 
/
 
 
 
 
 
/
 
 
 
 mice, as described
previously (15).
 
Preparation of Retroviral Gene Transfer System.
 
Mini-genes en-
coding OVA
 
257–269
 
, OVA
 
248–264
 
, and OVA
 
248–269
 
 were cloned
into pMSCVhyg (CLONTECH Laboratories, Inc.). PT67 pack-
 
*
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aging cells were transfected with 10 
 
 
 
g of these constructs by
DOTAP Liposomal Transfection Reagent (Boehringer). The
cells were selected by 300 
 
 
 
g/ml hygromycin for one week to
obtain stable virus-producing cell lines. The virus titers were 1–3 
 
 
 
10
 
7
 
 CFU/ml for OVA mini-genes, as evaluated by culture with
NIH3T3 cells. These supernatants were used for transfection
analysis. cDNA of human hsp90 was obtained by RT-PCR from
mRNA of peripheral blood mononuclear cells. For transfection
of genes of PA28
 
 
 
 or hsp90, cDNAs were cloned into 5
 
 
 
 HpaI
and 3
 
 
 
 EcoRI sites for PA28
 
 
 
 and XhoI site for hsp90 of pMSCV-
puro. (CLONTECH Laboratories, Inc.) and virus producing PT67
cells were selected by 2 
 
 
 
g/ml puromycin. E.G7 cells were trans-
fected by these retrovirus vectors and stable cell lines expressing
the molecules were established as E.G7 PA28
 
 
 
 and E.G7 hsp90
and E.G7 mock cells, then maintained in the presence of 5 
 
 
 
g/ml
puromycin.
 
Loading of Peptides by Osmotic Shock or Retrovirus Infection and
Antigen Presentation Assay.
 
Osmotic introduction of peptides or
proteins into EL4 cells was performed as described previously
(26). Briefly, 2 
 
 
 
 10
 
6
 
 pelleted cells were suspended in 200 
 
 
 
l
warm (37
 
 
 
C) hypertonic buffer (0.5 M sucrose in 10% wt/vol
polyethylene glycol 1,000 in RPMI) with or without synthetic
peptides and 100 
 
 
 
g of hsp90, hsc70, gp96, or recombinant
PA28 , and incubated for 10 min. Then, 15 ml of warm hypo-
tonic buffer (RPMI 1640/dH2O: 60%) was added immediately
followed by a 2-min incubation. After centrifugation, the cells
were washed twice and further incubated in the presence or ab-
sence of GA (5  M), HA (5  M), or lactacystin (LC; 50  M) in
serum-free RPMI for 3 h at 37 C, under 5% CO2. For retroviral
expression of OVA peptides, 5   105 EL4 cells were transfected
for 3 h by retrovirus vector encompassing mini-genes encoding
OVA257–269, OVA248–264, and OVA248–269 at the doses indicated in
the figure legends, and then the virus was washed off. These cells
were labeled by 3.7 MBq Na2
51CrO4 (NEN Life Science Prod-
ucts) and used for standard 51Cr-release assay. The CTL assay was
performed in the presence of brefeldin A (BFA) to block the
egress of newly assembled MHC class I molecules from the endo-
plasmic reticulum to the cell surface. In all cases, control cultures
were incubated in DMSO at a concentration equivalent to those
in the inhibitor preparations.
Western Blot Analysis. After disruption of the cells by sonica-
tion and centrifugation at 100,000 g for 1 h, the resulting super-
natant and precipitate were used as the cytosol and membranous
fractions, respectively. The resultant total materials were dissolved
with sample buffer for SDS-PAGE and run on a SDS-PAGE gel,
blotted onto a PVDF membrane, and probed with anti-hsp90
mAb (rat IgG, SPA-835, clone 16F1; StressGen Biotechnologies),
anti- 2 microglobulin (M-20: affinity purified goat polyclonal an-
tibody; Santa Cruz Biotechnology, Inc.), anti-hsp70 mAb (rat
IgG, SPA-815, clone 1B5; StressGen Biotechnology) and anti-
grp94 (gp96) mAb (rat IgG, SPA850; StressGen Biotechnology),
and anti-PA28 ,   rabbit polyclonal antibodies (15). Biotin-con-
jugated goat anti–rat Ig(Fc) or rabbit IgG (H L) was used as sec-
ondary Ab (Jackson ImmunoResearch Laboratories) and peroxi-
dase-conjugated avidin was used for visualization. The quantity of
each protein was assessed by densitometric analysis of ECL-ex-
posed films. Polyclonal antibodies against PA28  and PA28  and
transporter associated with antigen processing (TAP)2 were pro-
duced as serum from rabbits immunized with synthetic peptides,
human PA28 22–37 (CTKTENLLGSYFDKKI) and PA28 3–18
(KPCGVRLSGEARKQVE) and human TAP2688–703
(CCQEGQDLYSRLVQQRLMD), respectively, and purified
with peptide bound affinity columns.
RT-PCR. RT-PCR was used for quantification of tran-
scripts of Kb and its control glyceraldehyde-3-phosphate dehy-
drogenase (G3PDH). For the amplification of Kb transcript,
forward primer CCGAATTCATGGTACCGTGCACGCTGC
and reverse primer CCTCTAGATCACGCTAGAGAAT-
GAGG were used. For the amplification of G3PDH, ACCA-
CAGTCCATGCCATCAC and TCCACCACCCTGTTGCT-
GTA for forward and reverse primers were used.
Flow Cytometric Analysis. Cells were incubated for 30 min
with ascites obtained from 25.D1–16 hybridoma (murine IgG1,
specific for Kb-OVA257–264 [28], a gift from Dr. R. Germain, Na-
tional Institutes of Health, Bethesda, MD) at 4 C, then washed
twice followed by staining with FITC-conjugated rabbit anti–
mouse IgG (H L; Jackson ImmunoResearch Laboratories) for
30 min at 4 C. For staining of Kb molecules, biotin-conjugated
anti–mouse Kb mAb derived from CTKb (Cedarlane Laborato-
ries) and FITC-conjugated streptavidin (Jackson ImmunoRe-
search Laboratories) were used. For staining of LFA-1, M17/4.2
(rat IgG2a) and FITC-conjugated mouse anti–rat Ig(H L) were
used. The acid wash recovery assay was performed, as described
previously (29). Briefly, cells were treated for 1.5 min with acid
(1:1 mixture of 0.263 M citric acid and 0.132 M NaH2PO4 at
pH 3.0), neutralized to pH 7.5 by adding 1 ml of 0.15 M
NaH2PO4 and washed twice with PBS. The treated cells were
further incubated for 3 h with GA or OVA257–264 in the presence
or absence of IFN-  before FACS® analysis. Flow cytometric
analysis was performed with FACScan™ (Becton Dickinson),
and the data were analyzed by CELLQuest™ (Becton Dickin-
son). The experiments with FACScan™ were performed several
times and results of one representative experiment are shown.
The relative fluorescence was calculated after subtraction of the
fluorescence of control (staining with only second antibody or
FITC-conjugated streptavidin).
Results
Presentation of OVA Peptides Introduced by Osmotic Shock or
Retrovirus Infection. To monitor MHC class I antigen pro-
cessing pathway, we used a well-characterized Kb-restricted
OVA257–264 dominant antigen. Graded doses of synthetic
peptides extending COOH-terminally (OVA257–269), NH2-
terminally (OVA248–264), or both sides of the epitope
(OVA248–269) were osmotically introduced into EL4 cells.
Alternatively, these peptides were ectopically expressed by
infection of a retrovirus encoding each of these peptides.
Then, antigen presentation was measured by a standard
51Cr-release CTL assay using CTLs specific for OVA257–264.
As shown in Fig. 1 a, cytolysis was dependent on the dose
of peptides and on the virus titers. Cytolysis was observed
in RMA cells, but not in TAP-2-mutated RMA-S cells
(Fig. 1 b), indicating that the presentation of OVA248–269 is
TAP-dependent. In addition, a proteasome inhibitor LC
completely abolished the killing of EL4 cells expressing
OVA257–269 and OVA248–269, but not OVA248–264 (Fig. 1 b),
indicating that the proteasome is involved in the processing
of COOH- but not NH2-terminally extended peptides, as
reported previously (30).
Enhanced Presentation of OVA Peptide by PA28  and
hsp90. Next, we examined the roles of hsp90 and PA28
on OVA antigen presentation. Loading of hsp90, rPA28 ,188 PA28 and hsp90 in MHC Class I Antigen Processing
gp96, and hsc70 by osmotic shock resulted in  2-3-fold
increase of each protein in both the cytosol and membra-
nous fractions of the EL4 cells compared with nonloaded
cells (Fig. 2 a). OVA248–269 was introduced with PA28  or
hsp90 into EL4 cells by osmotic shock, and the presenta-
tion was assessed by CTL assay. Cytolysis was enhanced by
hsp90 or PA28  but not by gp96, hsc70, or BSA (Fig. 2
b). We then examined the effects of GA or HA. Pretreat-
ment of hsp90 with GA or HA in vitro abrogated the ef-
fect of hsp90, indicating the ATPase activity of hsp90 is re-
quired for hsp90-mediated antigen presentation. Although
gp96, which is an endoplasmic reticulum (ER) resident
member of Hsp90 family, is known to have a peptide
chaperoning property similar to hsp90, it did not show any
effect, suggesting that hsp90-assisted presentation is not
simply due to its activity as a molecular chaperone that
may protect the peptides from nonspecific degradation. It
was previously reported that hsp90-peptide complex is
Figure 1. Presentation of OVA pep-
tides introduced by osmotic shock or
retrovirus transfection. (a) Dose-depen-
dent effects of OVA peptides for CTL
assay. (Top panel) EL4 cells were os-
motically loaded with graded doses of
synthetic peptides. 30  g ( ), 10  g
( ), 1  g ( ), 0.1  g ( ). 30  g of
OVA257–269, OVA248–264, or OVA248–269
corresponds to 19.1 nmol, 15.4 nmol, or
11.7 nmol, respectively. (Bottom panel)
EL4 cells were transfected for 3 h by
pMSCV retrovirus vector encompassing
mini-genes encoding OVA257–269 (3  
107 CFU/ml), OVA248–264 (3   107
CFU/ml), or OVA248–269 (107 CFU/
ml). The titration of the supernatants
used for transfection was 1 ( ), 1/10 ( ), 1/100 ( ), and 1/500 ( ). These OVA-introduced EL4 cells were labeled with Na2
51CrO4 and used as targets
for lysis by OVA257–264 specific CTLs. (b) TAP- and proteasome-dependency of OVA peptide presentation. OVA257–269, OVA248–264, and OVA248–269
were osmotically introduced (4 nmol each peptide) or transfected (retrovirus solution: 3   106 CFU/ml) into 5   105 RMA, RMA-S, EL4, or LC (50
 M)-treated EL4 cells, as indicated. These cells were used as target cells for the CTL assay (E/T ratio   10).
Figure 2. Effects of hsp90 and PA28  on
OVA248–269 peptide presentation. (a) Levels
of introduced proteins. After osmotic intro-
duction of hsp90, rPA28 , gp96, and hsc70
into EL4 cells, the cytosol and membrane
fractions were used for Western blot analy-
sis. Closed and open triangles indicate en-
dogenous and rPA28 , respectively. (b)
Augmentation by hsp90 and rPA28 
on presentation of OVA248–269 peptide.
OVA248–269 (3 nmol) was osmotically intro-
duced into EL4 cells with or without hsp90,
rPA28 , gp96, hsc70, and BSA. After hsp90
and rPA28  were treated for 1 h at 37 C
with or without GA or HA in vitro, un-
bound ansamycin drugs were removed by
extensive washing with PBS using an ul-
trafree-15 centrifugal filter device, before
osmotic introduction and used for introduc-
tion, as indicated. These EL4 cells were
used as target cells in CTL assay (E/T ratio
10 [ ]; E/T ration 5 [ ]). (c) The antigen
processing after simultaneous or sequential
introduction of OVA248–269 and hsp90.
OVA248–269 was routinely introduced by ad-
mixing of the peptide and hsp90 (simulta-
neous introduction) into EL4 cells. For se-
quential introduction, after OVA248–269 (3
nmol) was introduced and immediately after
washing off the peptide, hsp90 was loaded
into EL4 cells.189 Yamano et al.
more active in antigen presentation than free peptides
when loaded into cells, presumably due to its chaperone
activity (31). To minimize the effect of hsp90 as a chaper-
one, we sequentially loaded peptide and hsp90 (first pep-
tide, second hsp90), and cytolysis by CTLs was examined.
As shown in Fig. 2 c, sequential loading obviously en-
hanced the presentation of the peptide compared with
loading peptide alone and was comparable to that of ad-
mixing of Hsp90 and peptides. This result also suggests
that hsp90 enhances antigen presentation in a novel fash-
ion other than chaperoning peptides.
Accelerated Processing of COOH-terminally Extended Pep-
tides by PA28  and hsp90. To further analyze the effects
of PA28  and hsp90, we introduced the three OVA pep-
tides with or without PA28  and hsp90 and measured
antigen presentation by quantifying the cell-surface Kb-
OVA257–264 complex using mAb 25D.1–16 (28) as a func-
tion of time (at 0, 4, and 8 h). As shown in Fig. 3, a and b,
when COOH-terminally extended peptides (OVA257–269,
OVA248–269) were introduced without PA28  or hsp90, the
cell surface expression of Kb-OVA257–264 complex reached
the maximum level 8 h after introduction, whereas coin-
troducing PA28  or hsp90 caused rapid presentation of the
complex, resulting in maximum expression level after 4 h,
although their intensities were nearly equal to each other.
In contrast, NH2-terminally extended peptide, OVA248–264,
was processed and presented regardless of the presence or
absence of PA28  or hsp90. 12 h after peptide loading, the
expression of Kb-OVA257–264 complex in each case de-
creased (data not shown). Subsequently, we also performed
CTL assay. Three peptides were introduced into EL4 cells
either by osmotic shock or retrovirus infection together
Figure 3. Hsp90 and PA28 
augment the presentation of
COOH- but not NH2-termi-
nally extended OVA peptides. (a
and b) FACS® analysis. To ob-
tain clear visualization of cell-
surface Kb-OVA257–264 complex,
large amounts of OVA257–269 (30
nmol), OVA248–264 (30 nmol),
and OVA248–269 (25 nmol) pep-
tides were introduced by os-
motic shock, with or without
rPA28  (a) or hsp90 (b). Staining
with mAb 25.D1–16 followed
by FITC-conjugated anti–mouse
secondary Abs was performed 0,
4, and 8 h after introduction.
Gray shadows indicate staining
only with secondary Abs. (c and
d) CTL assay. OVA257–269,
OVA248–264, and OVA248–269 (4
nmol each) were osmotically in-
troduced or transfected by retro-
virus solution with or without
rPA28  (c) or hsp90 (d) into
EL4 cells pretreated with or
without LC (50  M). For retro-
virus transfection, EL4 cells were
infected for 3 h by retrovirus
solution (3   106 CFU/ml) im-
mediately after osmotic intro-
duction of rPA28  or hsp90.
These cells were used as target
cells in CTL assay. (e) Dose-
dependent effects of OVA257–269
and OVA248–264 peptides for CTL
assay. OVA257–269 and OVA248–264
were titrated as indicated and os-
motically introduced into EL4
cells with or without rPA28 
and hsp90, then the cytolysis by
CTLs was determined. These
EL4 cells were used as target
cells in CTL assay (E/T ratio 10
[ ]; E/T ratio 5 [ ]).190 PA28 and hsp90 in MHC Class I Antigen Processing
with rPA28  or hsp90. rPA28  (Fig. 3 c) or hsp90 (Fig. 3
d) enhanced the cytolysis of cells expressing COOH- but
not NH2-terminally extended peptides. These enhance-
ments by both proteins were completely abolished when
EL4 cells were pretreated with LC, suggesting that hsp90 as
well as rPA28  are functionally linked to the activity of the
20S proteasome. As shown in Fig. 3 e, PA28  and hsp90
appreciably augmented the processing of OVA257–269, at
any concentration of the peptides, while they had no effect
on the processing of OVA248–264 even at a limiting concen-
tration. These data indicate that PA28 and hsp90 accelerate
the processing of the COOH-terminally extended OVA
peptides by the proteasome without changing its substrate
specificities. It is of note that hsp90 did not affect the pre-
sentation of NH2-terminally extended peptide, precluding
again the effect of hsp90 as peptide chaperone and indicat-
ing that hsp90 acts through the function of the proteasome
as PA28.
Geldanamycin Suppresses OVA Presentation in LPS Blasts
Derived from PA28  / /  /  But Not PA28  / /  / 
Mice. We next examined the epistasis of PA28- and
hsp90-mediated pathways. We previously reported that the
generation of OVA257–264 epitope is not affected in
PA28  / /  /  LPS blasts (15) and expression of total Kb
of LPS blasts derived from PA28  / /  /  and PA28  / /
  /  mice is almost comparable (data not shown), suggest-
ing that there exists an alternative pathway for antigen pro-
cessing, which compensates for the loss of PA28 in
PA28  / /  /  LPS blasts. To test whether hsp90 acts in
place of PA28 in these cells, LPS blasts from PA28  / /
  /  and PA28  / /  /  mice were treated for 1.5 h
with GA before osmotic loading of the three OVA pep-
tides, and antigen presentation was monitored by CTL as-
say. Consistent with our previous report (15), the genera-
tion of OVA257–264 epitope was not influenced by the
absence of PA28. Furthermore, GA had no effect on
PA28  / /  /  cells. Surprisingly, the processing of
COOH-terminally extended peptides was profoundly in-
hibited by GA in PA28  / /  /  blasts (Fig. 4 a, top and
middle panels). GA had no effect on the presentation of
NH2-terminally extended peptide (OVA248–264) irrespec-
tive of the presence of PA28  . To examine whether the
role of hsp90 is restricted in PA28  / /  /  LPS blasts or
generally observed in other cells, we assessed the OVA
epitope presentation in EL4 cells pretreated with GA or
HA. As shown in Fig. 4 a (bottom panel), partial inhibition
by GA or HA was observed in EL4 cells loaded with
OVA257–269 or OVA248–269, but not in cells loaded with
OVA248–264.
To verify that the loaded peptide OVA248–264 were pro-
cessed and presented internally in cells, we treated LPS
blasts and EL4 cells with BFA during antigen processing and
performed CTL assay. BFA treatment completely inhibited
the presentation of the peptide, and pulsing of the epitope
peptide to BFA treated cells restored the cytolysis (Fig. 4 b).
The processing of COOH-terminally extended peptides
OVA257–269 or OVA248–269 was also inhibited by BFA (data
not shown) like LC (Fig. 3, c and d), indicating that all pep-
tides used were processed and presented internally in cells.
These results indicate that the hsp90-dependent process-
ing pathway is common, but the contribution of hsp90 in
antigen processing seems to depend on the cell type. As re-
ported previously (15), PA28  / /  /  LPS blasts almost
completely lost the ability to process a melanoma antigen
TRP-2 peptide (TRP2181–188), indicating that PA28 is defi-
nitely required for this antigen presentation. Considering
the partial suppression by GA or HA for OVA257–264 pre-
Figure 4. Effects of geldanamycin on antigen presentation in
PA28  / /  /  and PA28  / /  /  blasts and EL4 cells. (a) OVA257–
269, OVA248–264, and OVA248–269 (4 nmol each) were osmotically intro-
duced into LPS blasts of PA28  / /  /  and PA28  / /  /  mice or
EL4 cells pretreated with GA ( ) or HA ( ) or untreated ( ) for 1.5 h.
These cells were used as target cells in CTL assay. (b) BFA dependency
on antigen presentation. OVA248–264 was osmotically introduced into EL4
cells pretreated with ( ) or without ( ) 5  g/ml BFA. BFA was treated
1 h before the introduction of peptide and continued for 3 h with ( ) or
without ( ,  ) pulsation of OVA257–264 in EL4 cells. The 51Cr-release
assay was performed as in panel a. (c) TRP2181–193 and OVA248–269 (4
nmol each) were osmotically introduced, with PA28  ( ), hsp90 ( ), or
alone ( ) into EL4 cells pretreated with GA ( ) or LC ( ) for 1.5 h.
These cells were used as target cells in CTL assay.191 Yamano et al.
sentation in EL4 cells, it is interesting to test how PA28 or
hsp90 affects the TRP2181–188 presentation in these cells.
We introduced TRP2181–193 (COOH-terminally extended)
or OVA248–269, together with rPA28  or hsp90, into EL4
cells pretreated with or without GA. As shown in Fig. 4 c,
neither hsp90 nor GA-treatment influenced the presenta-
tion of TRP2181–188, whereas rPA28  considerably in-
creased the presentation of this epitope, suggesting that
presentation of TRP2181–188 is absolutely dependent on
PA28 and that hsp90 does not have any role for this
epitope. On the other hand, experiments using OVA248–269
again showed that both PA28  and hsp90 contributed to
the presentation of the epitope in EL4 cells (Fig. 4 c), indi-
cating that these two pathways operate in these cells. Taken
together, the PA28- and the hsp90-dependent pathways for
antigen processing can work both redundantly and specifi-
cally, which depends on the type of antigen.
IFN-  Increases Dependency on PA28 Rather Than hsp90.
It is clear that both the PA28- and hsp90-dependent path-
ways for OVA epitope presentation operate redundantly in
wild-type LPS blasts and EL4 cells, but the PA28-depen-
dent pathway seems to be dominant in LPS blasts com-
pared with EL4 cells, based on GA sensitivity. The differ-
ence may be due to the balance of PA28 and hsp90
expression. Therefore, we next examined the effect of
IFN-  on the two pathways of antigen processing in E.G7
cells, which express the full-length OVA protein. We
transfected retrovirus vectors encoding cDNAs of either
PA28  or hsp90 into E.G7 cells, and measured the cell-
surface quantity of Kb-OVA257–264, with or without GA
and/or IFN-  treatment. The total cell extracts from these
transfected cells resulted in 2–3-fold increase in hsp90 or
PA28 , as determined by densitometric analysis (Fig. 5 a,
top panel). Whereas both PA28  and hsp90 enhanced the
expression of Kb-OVA257–264 complex, the stimulatory ef-
fect of hsp90, was completely prevented by GA treatment,
unlike PA28  (Fig. 5 b). Interestingly, preincubation with
IFN-  for 24 h markedly induced both PA28  and PA28 
(Fig. 5 a, bottom panel), and at the same time almost com-
pletely abrogated the inhibitory effect of GA (Fig. 5 b).
This observation was further confirmed by an acid-wash
recovery assay. E.G7 cells preincubated with or without
IFN-  were briefly exposed to acid medium (pH 3.0) in
order to destroy surface MHC-peptide complexes of cells,
and then monitored the recovery of Kb-OVA257–264 com-
plex expression. As shown in Fig. 5 c, GA significantly sup-
Figure 5. Effects of geldanamycin and
IFN-  on Kb-OVA257–264 complex expression
and CTL assay. (a) Levels of expressed pro-
teins. The hsp90, PA28 , and PA28  in to-
tal cell extracts of E.G7 mock, E.G7 hsp90,
E.G7 PA28  that had been prepared by
dissolving with the sample buffer for SDS-
PAGE were examined by Western blot
analysis. The expression of PA28  and  
were examined after culture with IFN- 
(50 U/ml) for the indicated periods. All the
quantity of each protein was assessed by
densitometric analysis of ECL-exposed
films. (b) FACS® analysis in OVA-express-
ing E.G7 cells. E.G7 cells were transfected
with retrovirus vector containing cDNA of
PA28  or hsp90 or mock and established,
as described in Materials and Methods.
These cells were incubated in the presence
or absence of IFN-  (50 U/ml) for 36 h.
During the last 12 h of incubation, the cells
were treated with or without GA (5  M),
and stained with mAb 25D.1–16 for the
analysis of the expression of Kb-OVA257–264
complex by FACS® and the results are
shown as relative fluorescence. (c) Acid
wash recovery assay. E.G7 cells that had
been preincubated in the presence or ab-
sence of IFN-  (50 U/ml) for 36 h were
acid (pH 3.0) treated. The E.G7 cells were
cultured with GA ( ), without ( ) GA 1 h
before acid washing and during the follow-
ing incubation in the presence or absence of
IFN- , then the expression of Kb–OVA257–264
complex was examined with mAb 25D.1–16
at indicated periods after acid treatment. (d)
CTL assay in EL4 cells. OVA248–269 (4
nmol) was osmotically introduced into EL4
cells pretreated with or without GA or LC (50  M). These cells were used as target cells in a 51Cr-release assay. The same experiment was also per-
formed with EL4 cells that had been cultured with 50 U/ml IFN-  for 24 h.192 PA28 and hsp90 in MHC Class I Antigen Processing
pressed the recovery of Kb-OVA257–264 complex, but this
suppression was cancelled by treatment with IFN- . These
results were also confirmed by CTL assays, in which
OVA248–269 was introduced into EL4 cells pretreated with
or without GA. As shown in Fig. 5 d, GA considerably in-
hibited OVA presentation in EL4 cells that were not
treated with IFN- , whereas no significant suppression of
cytolysis by GA was observed when EL4 cells were cul-
tured in the presence of IFN-  for 24 h before subjected to
the CTL assay.
We also tested the expression of total Kb molecules on
cell surface of E.G7 cells transfected with mock, PA28  or
hsp90 cDNA. To exclude the possible nonspecific influence
of GA on the stability of cell-surface molecules, we also ex-
amined the surface expression of LFA-1. As shown in Fig. 6
a, Kb expression was significantly suppressed by GA, espe-
cially in E.G7 hsp90, whereas that of LFA-1 was not af-
fected. The GA-dependent reduction of Kb was completely
restored to the level of E.G7 mock cells by incubation with
the Kb ligand OVA257–264 (Fig. 6 b), indicating that the re-
duction of Kb was due to a disturbed supply of Kb ligands.
Incubation of E.G7 cells with IFN-  greatly enhanced the
expression of surface Kb molecules, which could not be in-
hibited by GA (Fig. 6 b). These results were further con-
firmed by an acid-wash recovery assay as mentioned above.
As shown in Fig. 6 c, GA significantly inhibited the recov-
ery of Kb, which was restored by incubation with the
epitope peptides, but IFN-  abrogated the inhibition.
Figure 6. Effects of geldanamycin and
IFN-  on total Kb expression in E.G7 cells.
(a and b) Expression of Kb and LFA-1 mole-
cules. E.G7 mock, E.G7 PA28 , and E.G7
hsp90 cells were cultured in the presence or
absence of GA (5  M) with or without
OVA257–264 (10  g/ml), for 12 h. The ex-
pression of Kb and LFA-1 molecules on
these cells was examined with biotin-conju-
gated mAb CTKb and M17/4.2, respec-
tively, followed by staining with avidin-
FITC. Results are shown as a histogram (a)
and as relative mean fluorescence (b). The
experiments were also performed with the
transfectants, which were precultured in the
presence of IFN-  for 24 h. In a, the gray
shadows indicate staining only with avidin-
FITC. (c) Acid-wash recovery assay. E.G7
cells were treated with acid in the presence
or absence of IFN-  as in Fig. 5 c. The
E.G7 cells were cultured with GA ( ), GA
and OVA257–264 ( ), without ( ) GA 1 h
before acid washing and during the follow-
ing incubation in the presence or absence
of IFN- , then the expression of total Kb
was examined at indicated periods after
acid treatment.193 Yamano et al.
These results suggest that IFN-  treatment reduces the con-
tribution of the hsp90-dependent processing pathway.
Finally, we examined whether IFN-  can induce the cell
surface expression of Kb molecules in cells derived from
PA28  / /  /  mice. To this end, peritoneal macro-
phages (M ) were prepared from PA28  / /  /  mice and
tested for Kb expression on their cell surfaces. IFN-  mark-
edly enhanced cell surface Kb expression in wild-type M ,
however, no induction of Kb was observed in PA28  / /
  /  M  (Fig. 7, a and b) and pulsing of OVA257–264 pep-
tides to IFN- –treated PA28  / /  /  M  markedly in-
creased the expression of Kb to a level comparable with that
of wild-type cells (Fig. 7 b). These results indicate that
PA28-deficient cells induce Kb molecules as well as wild-
type cells upon IFN-  stimulation, but that Kb ligands were
not supplied in sufficient amount in PA28-deficient cells.
In other words, PA28-dependent pathway is the main
route responsible for antigen processing when cells were
stimulated with IFN- . Another important feature is the
profound inhibition of Kb expression by GA in IFN- -
treated PA28  / /  /  M , which was in contrast to that
in wild-type M  (Fig. 7 b). Similar results were obtained
Figure 7. Lack of IFN- –
dependent induction of cell sur-
face Kb molecules in macrophages
derived from PA28  / /  / 
mice. (a) Effects of IFN-  on Kb
expression in peritoneal macro-
phages of PA28  / /  /  and
PA28  / /  /  mice. Perito-
neal macrophages (M ) of
PA28  / /  /  or PA28  / /
  /  mice were incubated in the
presence or absence of IFN-  for
48 h and the resulting cell surface
expression of Kb was examined
with FACS® analysis as indicated
by arrows. (b) Effects of OVA257–
264 pulse of Kb expression on M 
from PA28  / /  /  and
PA28  / /  /  mice. These
macrophages were treated with
or without GA for the last 12 h
of incubation in the presence or
absence of OVA257–264 peptide
simultaneously. The results ob-
tained are represented as histo-
grams showing the relative fluo-
rescence. (c) Acid wash recovery
assay. Peritoneal macrophages of
PA28  / /  /  or PA28  / /
  /  mice were treated with
acid in the presence or absence
of IFN-  as in Fig. 5 c. These
cells were cultured with GA ( ),
GA and OVA257–264 ( ), without
( ) GA 1 h before acid wash and
during the following incubation
in the presence or absence of
IFN- , then the expression of
total Kb was examined at indi-
cated periods after acid treat-
ment. (d) Effect of IFN-  on the
expression of Kb and  2-m in
PA28–deficient MEFs. The ex-
pression of heavy chain (Kb) and
 2 microglobulin ( 2-m) of em-
bryonic fibroblasts (MEFs) of
PA28  / /  /  and PA28  / /
  /  mice was induced by IFN- .
RNAs for RT-PCR were ex-
tracted from MEFs of PA28  / /
  /  and PA28  / /  /  mice that had been cultured in the presence or absence of IFN-  (50 U/ml) for 48 h and 40 and 4 ng RNA was used for RT-
PCR of Kb and G3PDH, respectively. The RT-PCR products of Kb and G3PDH after 10 to 30 cycles were run onto 2% agarose gel electrophoresis and
stained with ethylene bromide. Total cell lysates for immunoblotting (IB) were prepared from 8   104 MEFs of PA28  / /  /  and PA28  / /  / 
mice that had been treated with IFN-  as mentioned above. The lysates were run on a 15% SDS-PAGE, transferred to a nitrocellulose membrane followed
by blotting with specific antibody.194 PA28 and hsp90 in MHC Class I Antigen Processing
using both bone marrow–derived dendritic cells and MEFs
(data not shown). These intriguing observations were con-
firmed by the acid-wash recovery assay. Indeed, in the ab-
sence of IFN- , GA completely inhibited the recovery of
Kb expression on M  of PA28  / /  /  and partially of
PA28  / /  / , which was restored by incubation with
pulsing of OVA257–264. Treatment with IFN-  significantly
enhanced the level of Kb expression of wild-type M  and
the enhanced Kb expression was not inhibited by GA. On
the other hand, IFN-  treatment of PA28  / /  /  M 
did not enhance Kb expression, although OVA257–264 puls-
ing enhanced the Kb expression to a level similar to that of
the wild-type cells treated with IFN-  (Fig. 7 c). The ex-
pression of heavy chain of Kb and  2 microglobulin was
normally induced by IFN-  in MEFs derived from
PA28  / /  /  mice, as assessed by RT-PCR and West-
ern blotting, respectively (Fig. 7 d), which is consistent
with the enhancement of Kb expression when OVA257–264
was pulsed. Furthermore, GA treatment completely inhib-
ited Kb expression on PA28  / /  /  M  even when
they were treated by IFN- . In addition, there was no dif-
ference in TAP2 induction by IFN-  between wild-type
and PA28-deficient cells (data not shown), showing IFN- 
signaling and MHC class I assembly components were
apparently normal in PA28-deficient mice. Taken to-
gether, our results indicate that in IFN-  treated cells
PA28-dependent pathway is dominant for epitope supply
to MHC class I molecules, whereas hsp90-dependent
pathway becomes negligible, even for epitopes processed
by both pathways under normal circumstances such
as OVA.
Discussion
In this study, we provide evidence to show the existence
of two distinct pathways responsible for generation of
MHC class I ligands, one is hsp90 dependent and the other
PA28 dependent. These two pathways were clearly charac-
terized by using hsp90-specific inhibitors GA and HA and
cells derived from PA28  / /  /  mice. Our results
showed that antigen presentation in LPS blasts of PA28  / /
  /  mice was profoundly inhibited by GA, whereas GA
never and only partially inhibited the generation of
OVA257–264 epitope in PA28-positive LPS blasts and EL4
cells, respectively, indicating that these two pathways co-
operate in these cells (Fig. 4 a). In contrast, in the absence
of GA treatment, the generation of OVA epitope was not
impaired in PA28  / /  /  blasts and rather comparable
to that of PA28  / /  /  blasts (Fig. 4 a), consistent with
our previous findings (15). In addition, the presentation of
OVA257–264 epitope from native OVA was clearly enhanced
by PA28  and hsp90 (Fig. 5 b). The enhancement by
hsp90 but not by PA28  was almost completely inhibited
by GA, indicating that the ATPase activity of hsp90 is re-
quired for antigen presentation although GA inhibits not
only hsp90 but also gp96 in the ER. Taken together, our
results indicate that PA28 and hsp90 redundantly contrib-
ute to the OVA257–264 epitope-processing pathway. It is
clear that hsp90 plays an essential role in the presentation of
OVA257–264 epitope in the absence of PA28, which was
clearly demonstrated using GA-treated PA28  / /  / 
LPS blasts, whereas PA28 is dominant in PA28  / /  / 
LPS blasts.
On the other hand, presentation of TRP2181–188 epitope
was solely dependent on PA28, even in the presence of
hsp90 in PA28  / /  /  LPS blasts. Consistent with this
observation, rPA28  had a stimulatory effect on the
TRP2181–188 processing in EL4 cells, whereas introduction
of hsp90 and GA treatment had no effect (Fig. 4 c, left
panel). Taken together, it is concluded that the two path-
ways mediated by hsp90 and PA28 redundantly contribute
to OVA processing, but the TRP2181–188 epitope processing
is specifically mediated by the PA28-dependent pathway.
Thus, it appears that utilization of these two pathways is
dependent on antigen species.
In wild-type LPS blasts and EL4 cells treated with IFN- ,
the PA28-dependent pathway is dominant, as GA had no
obvious inhibitory effects on OVA257–264 epitope genera-
tion (Figs. 4 a and 5, b–d). It is possible that the PA28-
dependent pathway suppresses the hsp90-dependent path-
way for processing of the same antigens. To understand this
phenomenon, it is essential to determine the molecular
mechanism of hsp90 involved in the MHC class I ligand
production. How can hsp90 activate antigen processing?
We first investigated whether hsp90 enhanced peptide hy-
drolyzing activity of the proteasome like PA28 in vitro, but
the results showed it did not (data not shown), consistent to
the previous reports (19, 20). In this regard, Goasduff and
Cederbaum (32) have recently reported that hsp90 inhib-
ited the cleavage of the fluorogenic peptide by purified
proteasome in vitro, whereas the use of hsp90 and cytosolic
fraction enhanced the hydrolysis, suggesting that hsp90 to-
gether with other unidentified cytosolic factors could acti-
vate the hydrolysis by the proteasome. Furthermore, sev-
eral studies have shown the binding of hsp90 to the 20S
proteasome (19, 20, and unpublished data). In considering
the redundant roles between PA28 and hsp90 pathways,
hsp90 (with or without other proteins) might be directly
involved in proteasome-dependent processing of antigens
by forming a complex with 20S proteasome, as PA28 does.
This model may explain in part the dominance of the PA28
over hsp90, although the role of the hsp90-proteasome
complex remains to be determined.
The results shown in Fig. 3, c and d, also suggested the
linkage of hsp90 and the proteasome. COOH- and NH2-
terminally extended OVA248–269 was presented more effi-
ciently than only NH2-terminally extended OVA248–264 by
PA28 and hsp90, while lactacystin blocked only the pre-
sentation of COOH-terminally extended peptides. This
suggests a mechanism that facilitates delivery of peptides
processed by the proteasome to the MHC class I assembly
system on the ER. In this regard, it is interesting that pro-
teasomes, PA28, and hsp90 are associated with the ER
membranes, probably the cytosolic face (33, 34), imaging a
speculative model that the proteasome processing machin-
ery involving PA28 and hsp90 may be directly linked to195 Yamano et al.
the TAP antigen transport system, as proposed previously
by Rechsteiner et al. (6). One may attribute the effect of
hsp90 to its function as a peptide carrier. Although we
showed in this study that enhanced processing of OVA
peptides by hsp90 was not attributed to its role as a peptide
chaperone because hsp90 did not affect the presentation of
NH2-terminally extended peptide and that the effect of
hsp90 was exactly linked to the proteasome, it is still possi-
ble that hsp90 plays a role as post-proteasomal peptide car-
rier. That is, hsp90 might bind peptides generated by the
proteasome and safely carry them to TAP transporter, pre-
venting further degradation by cytosolic peptidases as sug-
gested by Binder et al. (31). Indeed, when hsp90 and PA28
were osmotically introduced, their levels were increased 2–3-
fold in the cytosol as well as the membranous fractions (Fig.
2 a). Therefore, considerable amounts of transfected pro-
teins are thought to be associated with the membranes,
probably the ER, as considerable amounts of hsp90 and
PA28 were recovered in the membrane fractions in cells,
even without osmotic loading of these proteins (Fig. 2 a).
Another important aspect of the two distinct pathways is
their physiological roles. In this study, we provided evi-
dence that the PA28 pathway is up-regulated by IFN- . In
this context, we propose the existence of a constitutive
pathway and adaptive pathway regulated by IFN-  in
MHC class I antigen processing. The process requiring
hsp90 can be regarded as a constitutive pathway. On the
other hand, the PA28-mediated pathway can be regarded
as an adaptive pathway, because PA28 is markedly induced
by a major cytokine IFN- . In fact, we showed that GA
had no significant effect on OVA257–264 epitope generation
in PA28  / /  /  LPS blasts (Fig. 4 a). This is probably
because the PA28  / /  /  LPS blasts express a large
amount of PA28, and hence the hybrid proteasome. Con-
sistent with this model, GA had no effect on OVA257–264
epitope generation in IFN- –treated EL4 cells, neverthe-
less it considerably inhibited the presentation in E.G7 cells
without treatment with IFN-  (Fig. 5, b and c). In addi-
tion, GA treatment of E.G7 cells down-regulated the ex-
pression of total Kb molecules (Fig. 6) as well as Kb-
OVA257–264 complex on the cell surface (Fig. 5, b and c).
Conversely, transfection of hsp90 cDNA by retrovirus en-
hanced cell surface Kb molecules (Fig. 6 b) and other tumor
cell lines (data not shown). Regarding the expression of
Kb-OVA257–264 complex and total Kb, the inhibitory effect
by GA was abolished by incubation of cells with IFN- 
(Fig. 5, b and c, and Fig. 6, b and c). Thus, IFN-  shifts the
functional balance from hsp90 toward PA28. The defect of
IFN- –induced up-regulation of Kb molecules on cell sur-
face of macrophages (Fig. 7), dendritic cells, MEFs, and
LPS blasts (data not shown) derived from PA28  / /  / 
mice also supports this notion. The reason for this shift
could attribute to the fact that IFN-  can induce PA28, re-
sulting in an increase in the hybrid-proteasome (9). As
hsp90 was not induced by IFN-  (data not shown), the
substantial role of hsp90 in antigen presentation would be
replaced by abundant PA28. Indeed, down-regulation of
total Kb molecules by GA was markedly enhanced even in
IFN- –treated macrophages of PA28  / /  /  mice (Fig.
7 b), which was in contrast to that of wild-type mice.
In summary, we have reported a novel function for
hsp90, and demonstrated the crucial role of PA28 on IFN-
 –induced up-regulation of MHC class I molecules. Our
results provide fundamental insight into the function of
PA28 and hsp90 in MHC class I antigen processing/pre-
sentation.
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